Tirzepatides Gallery
$$MultiPurposeText$$
See examples of our Tirzepatides work and results.
Frequently Asked Questions
Get answers to common questions about Tirzepatides.
Tirzepatides activates both GLP-1 and GIP receptors, reducing appetite, slowing gastric emptying, and improving insulin sensitivity. This combined hormone action leads to reduced caloric intake and better glucose control, producing measurable weight loss when combined with lifestyle changes and clinical monitoring.
Ideal candidates include adults with obesity or overweight with metabolic risk, and some patients with type 2 diabetes. We perform a medical evaluation to assess suitability, review medications, and discuss goals, contraindications, and individualized treatment plans before starting therapy.
Common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and reduced appetite — usually occurring during dose escalation and often improving over weeks. Hydration, dose adjustments, and supportive care help; report severe or persistent symptoms so the provider can reassess treatment.
Many patients notice appetite suppression within the first weeks, with measurable weight loss appearing in four to twelve weeks. Optimal and sustained results typically occur over several months when therapy is continued alongside dietary changes and regular follow-up.
Yes. Tirzepatides is most effective when combined with diet, exercise, and behavior changes. Our team provides nutritional guidance and coaching to enhance results, and lifestyle modification remains essential for long-term weight maintenance and metabolic health.
Tirzepatides is given as a once-weekly subcutaneous injection. Treatment usually begins at a low dose and is titrated upward to balance effectiveness and tolerability. After training, injections can be self-administered at home with scheduled clinic follow-ups for monitoring.